SHR-A1811 plus other therapies for advanced HER2+ tumors
Part of Cancer clinical trials.
This trial tests a new medicine called SHR-A1811 combined with other cancer treatments for advanced solid tumors that have HER2 protein or HER2 mutations. It may help people whose cancer has not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of advanced cancer (solid tumor) that has spread or cannot be removed with surgery, and your tumor has HER2 protein or a HER2 gene change.
- You are willing to provide a tumor sample (either from a previous biopsy or a new one) within the last year.
- You have at least one tumor that can be measured on a scan (like a CT or MRI).
- You have not had certain other cancer treatments or conditions, like untreated brain metastases, serious lung disease, or recent major surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (SHR-1811) combined with a standard chemotherapy drug (carboplatin) for advanced breast cancer that shows HER2, even at low levels. It may offer a new option for people whose cancer has stopped responding to previous treatments.
This trial tests a new drug, SHR-A1811, given alone or followed by a standard treatment, before surgery for early-stage HER2-positive breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
This trial tests whether SHR-A1811 alone, or together with pyrotinib, given before surgery, can shrink HER2-positive breast cancer. It may help you respond better to treatment while making surgery easier.
This trial tests a new drug called SHR-A1811 for women with HER2-positive breast cancer that did not shrink enough after the first four rounds of chemotherapy before surgery. The goal is to see if this drug can improve outcomes for patients who need a different treatment approach.
This study tests a new drug called SHR-A1811, given by different methods, to find the best way to treat advanced HER2-positive breast cancer. It may help if you have had few treatments so far and have not had this type of drug before.
This early-phase trial tests an injectable cancer drug (SHR-A1811) given with either pyrotinib or another targeted drug (SHR-1316) in people with advanced lung cancer. The goal is to see how safe the combination is and how well it can control the cancer.
Hear when a new HER2-expressing Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.